A prospective, observer-blind, randomized clinical trial to investigate and compare the clinical efficacy of Chloroprocaine 3% gel and Oxybuprocaine 0.4% eye drops anesthesia for clinical practice in pediatric population.

You likely can't join if

• Patients fulfilling at the inclusion visit ONE OR MORE of the following exclusion criteria will not be enrolled in the study: Ophthalmic exclusion criteria 1. Previous ocular surgery less than 6 months before screening 2. Eye movement disorder (nystagmus) 3. History of herpetic keratitis 4. Corneal, epithelial, stromal or endothelial, residual or evolutionary disease (including corneal ulceration, corneal damage and superficial punctuate keratitis) 5. History of ocular traumatism, infection or inflammation within the last 3 months
• Systemic/non ophthalmic exclusion criteria • General history: 6. Any other medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine neoplasia, hematological diseases, severe psychiatric illness, cardiac rhythm disorders and/or any complicating factor or structural abnormality judged by the investigator to be incompatible with the study • Allergic history: 7. Known hypersensitivity to one of the components of the investigational products
• Exclusion criteria related to general conditions 8. Non-compliant patient and/or parent(s)/legal representative(s) (e.g., not willing to attend the follow-up visits, way of life interfering with compliance) 9. Participation in another clinical study in the last three months before this study. The 3-month interval is calculated as the time between the first calendar day of the month that follows the last visit of the previous study and the first day of the present study 10. Already included once in this study
• Exclusion criteria related to previous and concomitant medications / nonproduct therapies 11. Patient using any of the following previous and concomitant medication / treatment (according to the described periods) will not be included in the study: BEFORE INCLUSION (30,15,7 days) and Inclusion (day 1): Any change in concomitant anti-depressant medication, Any topical ocular treatment. BEFORE INCLUSION (15,7 days) and Inclusion (day 1): Systemic opioids and morphine drugs. BEFORE INCLUSION (7 days) and Inclusion (day 1): Any change in other systemic medication already ongoing before inclusion visit. Inclusion (day 1): Others systemic antalgics drugs*. *Paracetamol after primary endpoint assessment and oral, implantable, transdermal, or injectable contraceptives for child-bearing potential girls during the entire study will be allowed.